
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health continues to demonstrate strong financial performance with a 7% year-over-year growth, indicating resilience in a challenging market. The company maintains a dominant position in the comprehensive genomic profiling liquid biopsy market with over 50% market share and has experienced nearly 30% year-over-year growth, suggesting robust demand for its diagnostics services. Additionally, the recent advancements in reimbursement and pricing strategies for its Reveal and Shield testing products are expected to drive further expansion in average selling prices and test volumes, enhancing future revenue potential.
Bears say
Guardant Health faces significant challenges due to the potential decrease in reimbursement rates, which could negatively affect its average selling price (ASP) and overall revenue estimates. The outstanding PAMA regulations present a risk of a one-time revenue decline of approximately $100 million, further exacerbating financial uncertainties. Additionally, the regulatory landscape for multi-cancer early detection tests (MCED) remains nascent, leaving Guardant's ability to secure necessary reimbursements and drive adoption of its assays in question.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares